Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 688105.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688105.SS and 80,000+ other tickers.
See exactly how 688105.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688105.SS and 80,000+ other tickers.
Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodies, and unique polymer organic compounds. The company's extensive product portfolio encompasses a broad spectrum of scientific research reagents. This range features solutions for advanced techniques such as PCR cloning and point mutation, nucleic acid extraction, reverse transcription, quantitative PCR (qPCR), cell and protein analysis, gene editing…
No recent news available.